Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties

Area of Science:

• Pharmacology
• Infectious Diseases
• Drug Development

Background:

• Rising antimicrobial resistance in Gram-positive bacteria necessitates improved antibiotic treatments for acute bacterial skin and soft structure infections (ABSSSI).
• Current oritavancin formulations require lengthy infusions and large volumes, posing challenges for clinical administration.
• A novel oritavancin formulation was developed to enhance administration efficiency and flexibility.

Purpose of the Study:

• To evaluate the pharmacokinetic equivalence of a new oritavancin formulation compared to the current one.
• To assess the safety and tolerability of the new oritavancin formulation in patients with ABSSSI.
• To determine if the new formulation offers advantages in terms of infusion volume and time.

Main Methods:

• A randomized trial comparing the new and current oritavancin formulations in 102 adult patients with ABSSSI.
• Pharmacokinetic analysis focused on the relative area-under-the-curve (AUC) exposure over 72 hours postdose.
• Safety assessment included monitoring treatment-emergent adverse events, serious adverse events, and laboratory parameters.

Main Results:

• The new oritavancin formulation demonstrated pharmacokinetic exposure (AUC 0-72 hours) comparable to the current formulation.
• No significant differences in treatment-emergent adverse events were observed between the two groups.
• The safety profile of the new formulation was consistent with the established profile of the original oritavancin.

Conclusions:

• The new oritavancin formulation, with reduced infusion volume and duration, is pharmacokinetically equivalent to the original formulation.
• The enhanced formulation maintains a similar safety profile, offering a more convenient administration option for ABSSSI treatment.
• This development is crucial for combating Gram-positive bacterial infections amidst growing antimicrobial resistance.